• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
Right Arrow Button IconLeft Arrow Button IconHome
Right Arrow Button IconWegovy

Wegovy

Middle-aged adults taking GLP-1s for obesity can save over $192K on lifetime medical costs, higher if they don’t have college degrees, new study finds
Health
Middle-aged adults taking GLP-1s for obesity can save over $192K on lifetime medical costs, higher if they don’t have college degrees, new study finds
By Mia OsmonbekovJune 14, 2026
Adult obesity rate fell from record high—and big pharma is reaping the benefits from mainstream sales of weight-loss drugs like Zepound and Mounjaro
Health
Adult obesity rate fell from record high—and big pharma is reaping the benefits from mainstream sales of weight-loss drugs like Zepound and Mounjaro
By Matty Merritt and Morning BrewOctober 31, 2025
Novo Nordisk selects insider Maziar Mike Doustdar as new CEO, to tackle ‘recent market challenges’
C-Suite
Novo Nordisk selects insider Maziar Mike Doustdar as new CEO, to tackle ‘recent market challenges’
By AFPJuly 29, 2025
Ozempic CEO’s exit from Novo started with Teams call surprise
Finance
Ozempic CEO’s exit from Novo started with Teams call surprise
By Naomi Kresge and BloombergMay 16, 2025
Zepbound users lost nearly 50% more weight than those on Wegovy in first head-to-head study
Health
Zepbound users lost nearly 50% more weight than those on Wegovy in first head-to-head study
By Jonel Aleccia and The Associated PressMay 12, 2025
Karsten Munk Knudsen, chief financial officer of Novo Nordisk A/S, at the company's headquarters in Bagsvaerd, Denmark, on Tuesday, Nov. 26, 2024.
Health
Currency hedging and new U.S. factories: Novo Nordisk CFO thinks Wegovy maker can outmaneuver global trade wars
By Ryan HoggMay 9, 2025
Novo Nordisk slides on pressure from Lilly’s pill study
Retail
Novo Nordisk slides on pressure from Lilly’s pill study
By Marthe Fourcade and BloombergApril 22, 2025
Novo Nordisk CEO warns tariffs could send the prices of Ozempic and Wegovy higher
Finance
Novo Nordisk CEO warns tariffs could send the prices of Ozempic and Wegovy higher
By Chris MorrisMarch 7, 2025
Interest in GLP-1 medications like Ozempic will continue to grow given the multiple health conditions they can improve.
Commentary
The crisis over GLP-1 out-of-pocket costs deepens—it’s time for health-care leaders to step up
By Wendy BarnesMarch 4, 2025
Close up of a man's face
Health
50-year-old security guard lost 70 pounds on Wegovy—then gained two pants sizes when he lost insurance coverage
By Tom Murphy and The Associated PressFebruary 24, 2025
Semaglutide medications Wegovy and Ozempic are pictured
Health
Wegovy, Ozempic shortage declared over, hitting copycats like Hims & Hers
By Bloomberg, Madison Muller, Ike Swetlitz and Naomi KresgeFebruary 21, 2025
A woman injects herself with medication.
Health
Ozempic, Wegovy maker calls out Hims & Hers Super Bowl ad: ‘Check before you inject’
By Lindsey LeakeFebruary 11, 2025
Novo Nordisk President and CEO Lars Fruergaard Jorgensen testifies before the Senate Health, Education, Labor, and Pensions Committee in the Dirksen Senate Office Building on Capitol Hill on September 24, 2024 in Washington, DC. The committee heard testimony from Jorgensen about the price of popular pharmaceuticals made by Novo Nordisk that help treat diabetes and obesity, including Wegovy and Ozempic.
Leadership
As U.S. firms scrap diversity targets, the CEO behind Ozempic and Wegovy took a pay cut for missing them
By Ryan HoggFebruary 5, 2025
Karsten Munk Knudsen, chief financial officer of Novo Nordisk A/S, at the company's headquarters in Bagsvaerd, Denmark, on Tuesday, Nov. 26, 2024.
Health
As growth slows, CFO says Novo Nordisk is prepping for the next generation of weight loss drugs
By Ryan HoggFebruary 5, 2025
A person stands on a scale.
Health
Hims & Hers Super Bowl ad slams pricey pharma industry—and fumbles FDA warnings on compounded GLP-1 drugs
By Lindsey LeakeFebruary 3, 2025
1
  • 1
  • 2
  • 3
  • 4
  • 5
6
Most Popular
Big Tech
As Big Tech showers employees with perks to win the talent war, Nvidia built a nearly $5 trillion company by making people pay for their own lunchplaceholder alt text
By Marco Quiroz-GutierrezJuly 1, 2026
Success
MacKenzie Scott alone accounted for one-third of America's $19.2 billion in megagifts last yearplaceholder alt text
By Sydney LakeJune 25, 2026
Personal Finance
Current price of oil as of July 1, 2026placeholder alt text
By Joseph HostetlerJuly 1, 2026
Fortune Secondary Logo
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • World's Most Admired Companies
  • See All Rankings
  • Lists Calendar
Sections
  • Finance
  • Fortune Crypto
  • Features
  • Leadership
  • Health
  • Commentary
  • Success
  • Retail
  • Mpw
  • Tech
  • Lifestyle
  • CEO Initiative
  • Asia
  • Politics
  • Conferences
  • Europe
  • Newsletters
  • Personal Finance
  • Environment
  • Magazine
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
  • Group Subscriptions
About Us
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • Pinterest icon

© 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.